HUTCHMED (NASDAQ:HCM) Shares Gap Up to $18.16

HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report)'s share price gapped up before the market opened on Monday . The stock had previously closed at $18.16, but opened at $19.30. HUTCHMED shares last traded at $19.22, with a volume of 40,282 shares.

Analyst Upgrades and Downgrades

HCM has been the subject of several recent analyst reports. Cantor Fitzgerald restated an "overweight" rating on shares of HUTCHMED in a research note on Friday, January 12th. StockNews.com upgraded HUTCHMED from a "hold" rating to a "buy" rating in a research note on Wednesday, March 27th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, HUTCHMED has a consensus rating of "Moderate Buy" and a consensus target price of $29.70.

HUTCHMED Trading Up 4.1 %

The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.60 and a current ratio of 2.72. The firm's 50 day moving average is $16.59 and its two-hundred day moving average is $16.81.

Hedge Funds Weigh In On HUTCHMED

Institutional investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. increased its position in HUTCHMED by 353.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,593 shares of the company's stock valued at $65,000 after acquiring an additional 2,801 shares during the period. Vanguard Personalized Indexing Management LLC bought a new stake in shares of HUTCHMED during the third quarter valued at about $196,000. Hsbc Holdings PLC acquired a new stake in HUTCHMED in the third quarter worth about $380,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in HUTCHMED in the 3rd quarter valued at about $444,000. Finally, Hennion & Walsh Asset Management Inc. increased its stake in HUTCHMED by 89.5% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 51,735 shares of the company's stock valued at $876,000 after buying an additional 24,437 shares during the period. Institutional investors own 8.82% of the company's stock.

HUTCHMED Company Profile

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.